Early Metformin Treatment Linked to Halved Risk of Long COVID and Mortality

A widely used diabetes medication may offer a new defense against the lingering effects of SARS-CoV-2. Adults prescribed metformin within six days of a COVID-19 infection experienced a 53 percent lower risk of developing Long COVID or dying over the following six months, according to a new target trial emulation study.[1][2]

The findings, published in the Journal of Medical Virology, analyzed electronic health records from more than 21 million individuals. Researchers identified a stark contrast in outcomes between patients receiving early metformin and those prescribed other experimental treatments.[3][4]

While the results align with previous randomized trials, medical experts caution that the observational data cannot definitively prove prevention. The study highlights a potential low-cost intervention for a condition that continues to disrupt millions of lives globally.[3]

Long COVID, characterized by new or worsening symptoms that persist for months after the initial infection, remains a significant public health challenge. Finding an accessible, early-stage prophylactic could dramatically alter the trajectory of the disease for vulnerable populations.[1]

Emulating a Clinical Trial

To understand metformin's impact, researchers from the University of Minnesota Medical School utilized the National COVID Cohort Collaborative database. They designed a target trial emulation, a method that uses observational data to mimic the strict parameters of a randomized controlled trial.[2][4]

The team focused on adults who tested positive for COVID-19 between March 2020 and September 2023. They explicitly excluded patients who already had a clinical indication for metformin, such as prediabetes or type 2 diabetes, to isolate the drug's effect on the viral infection.[2][4]

Researchers compared 248 individuals who received a new metformin prescription within six days of infection against a control group of equal size. The control group received prescriptions for other medications during the same early window, serving as an active comparator.[1][2]

The comparison treatments included fluvoxamine, fluticasone, ivermectin, and montelukast. These medicines were utilized as an experimental baseline because they have been prescribed for acute COVID-19 but lack consistent trial evidence for preventing long-term symptoms.[2][3]

After applying statistical weighting to balance the groups, the demographic profile showed an average age of 53 years. Approximately 16 percent of the participants were Black, and 16 percent were Hispanic, with more than half of the cohort infected during the Omicron wave.[1][2]

Tracking the 53 Percent Reduction

The study tracked participants for 180 days to measure a composite primary outcome: a diagnosis of Long COVID or death. The results revealed a significant divergence in health trajectories between the two weighted cohorts over the six-month period.[2][3]

In the metformin group, 4.0 percent of patients—10 out of 248—developed Long COVID or died within the follow-up window. In contrast, the control group saw an 8.5 percent incidence rate, with 21 out of 248 patients experiencing the composite outcome.[1][3]

This 4.5 percentage point absolute risk reduction translates to an adjusted relative risk ratio of 0.47. Lead author Dr. Carolyn Bramante noted that the statistical data are highly compatible with a risk reduction ranging anywhere from 11 percent to 75 percent.[2][4]

"Metformin prescription within the week following documented SARS-CoV-2 infection was associated with a 53% reduction in LC/D over 6 months in this primarily Omicron-infected sample," wrote Dr. Bramante. The research team emphasized that replicating these results across different clinical environments is essential for updating treatment guidelines.[1][4]

The findings closely mirror the results of the randomized COVID-OUT trial, which Bramante also led. That earlier trial demonstrated that early metformin use cut the risk of Long COVID by approximately 40 to 50 percent with no significant safety concerns.[2]

Another recent sequential target trial analysis conducted in the United Kingdom assessed metformin started within 90 days of infection. That UK study reported a hazard ratio of 0.36, further corroborating the protective signal seen in the American cohort.[1]

Mechanisms of Protection

Metformin has been a cornerstone treatment for type 2 diabetes for decades, but its utility may extend far beyond blood sugar regulation. Researchers are increasingly focused on the drug's antiviral and anti-inflammatory properties during acute viral infections.[3]

During the early stages of COVID-19, systemic inflammation can trigger a cascade of complications that persist long after the virus clears. Metformin appears to mitigate this severe inflammatory response, potentially preventing the cellular damage associated with Long COVID.[3]

The drug may also inhibit viral replication directly within the host. By altering the cellular environment, metformin could lower the initial viral load, reducing the severity of the acute infection and limiting the virus's ability to establish long-term reservoirs.[3]

Timing appears to be the critical factor in unlocking these benefits. Administering the drug within the first six days of infection disrupts the disease pathway before the immune system becomes dangerously overactive.[1][2]

This early-intervention strategy contrasts sharply with recent negative trials for established Long COVID. Studies testing extended Paxlovid or colchicine in patients who already suffered from persistent symptoms showed no lasting clinical benefit.[2]

Methodological Limitations

Despite the promising figures, clinical methodologists urge careful interpretation of the study's design. Because the research relies entirely on electronic health records, it can only analyze what clinicians officially documented during medical visits.[3]

Analysts highlight the study's use of a composite endpoint, which combines Long COVID and death into a single metric. If metformin primarily reduced mortality rather than persistent symptoms, the composite score would still show a broad statistical benefit.[3][4]

The observational nature of the data also leaves room for unmeasured confounding factors. While entropy balancing adjusted for known variables like age and race, health records cannot capture every behavioral or clinical difference between the treatment groups.[2][3]

Furthermore, the absolute risk reduction of 4.5 percentage points means that roughly four to five fewer outcomes occurred per 100 people treated. Experts emphasize that these weighted estimates are population averages, not individual guarantees of prevention.[3]

Not every clinical trial has demonstrated the same degree of benefit. The ACTIV-6 randomized trial evaluated metformin in lower-risk adults and did not meet its prespecified efficacy threshold for reducing participant-reported persistent symptoms at six months.[3]

Clinical Implications and Next Steps

The replication of these results across different study designs strengthens the case for metformin as a prophylactic tool. However, medical professionals warn against patients seeking off-label prescriptions without direct clinical supervision and a thorough safety assessment.[1][3]

Metformin is generally safe, widely available, and inexpensive, making it an attractive candidate for global use. If incorporated into standard COVID-19 care protocols, it could offer a highly accessible defense against post-viral syndromes in lower-resource settings.[3]

The next phase of research will need to clarify the drug's specific impact on Long COVID independent of mortality. Future randomized trials must also determine the optimal dosing schedule and identify which patient populations stand to gain the most from early treatment.[2][4]

AI

For now, the findings provide a critical data point in the ongoing effort to manage the pandemic's long-term fallout. As millions continue to navigate the debilitating effects of Long COVID, early interventions remain the most viable strategy for safeguarding public health.[1][2]